GIS:FRA
Gilead Sciences, Inc
130,88 €
arrow_upward
+0,28%(+0,36) 1D
9. lis, 22:00:00 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za GIS...
Otvori
130,88 €
Najviša
130,88 €
Najniža
130,88 €
Trž. kap.
187,44 mlr.
Prosj. kol.
398,00
Količina
0,00
52-tjed. najviša
134,58 €
52-tjed. najniža
97,79 €
Broj djelatnika
17 tis.
Otvori
130,88 €
Najviša
130,88 €
Najniža
130,88 €
Trž. kap.
187,44 mlr.
Prosj. kol.
398,00
Količina
0,00
52-tjed. najviša
134,58 €
52-tjed. najniža
97,79 €
Broj djelatnika
17 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Trefis
·
prije 19 sati
Why Is Everyone Ignoring Gilead Stock’s High Cash Yield?
AD HOC NEWS
·
prije 1 dan
Gilead Sciences stock gains 2.23 percent after-hours to EUR 134.13
AD HOC NEWS
·
prije 1 dan
RBC raises target for Gilead Sciences stock to USD 126.00
Yahoo Finance
·
prije 2 dana
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences, Inc – informacije
Glavni izvršni direktorDaniel O'Day
Zaposlenici17 tis.
Osnovano22. lip 1987.
SjedišteFoster City, Kalifornija, Sjedinjene Američke Države
Sektor-
Web-lokacijagilead.com